396 related articles for article (PubMed ID: 33922362)
1. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.
Fiste O; Ntanasis-Stathopoulos I; Gavriatopoulou M; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Vaccines (Basel); 2021 Apr; 9(5):. PubMed ID: 33922362
[TBL] [Abstract][Full Text] [Related]
2. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma).
Jakubowski CD; Azad NS
Chin Clin Oncol; 2020 Feb; 9(1):2. PubMed ID: 32008328
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
Tian L; Ma J; Ma L; Zheng B; Liu L; Song D; Wang Y; Zhang Z; Gao Q; Song K; Wang X
World J Surg Oncol; 2020 Nov; 18(1):303. PubMed ID: 33228682
[TBL] [Abstract][Full Text] [Related]
5. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
6. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
7. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
Sui M; Li Y; Wang H; Luo Y; Wan T; Wang X; Hu B; Cheng Y; Lv X; Xin X; Xu Q; Wang G; Lu S
J Immunother Cancer; 2019 May; 7(1):125. PubMed ID: 31064408
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract][Full Text] [Related]
9. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options.
Personeni N; Lleo A; Pressiani T; Colapietro F; Openshaw MR; Stavraka C; Pouptsis A; Pinato DJ; Rimassa L
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202975
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report.
Liu ZL; Liu X; Peng H; Peng ZW; Long JT; Tang D; Peng S; Bao Y; Kuang M
Front Med (Lausanne); 2020; 7():368. PubMed ID: 32984358
[TBL] [Abstract][Full Text] [Related]
11. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
Lu JC; Zeng HY; Sun QM; Meng QN; Huang XY; Zhang PF; Yang X; Peng R; Gao C; Wei CY; Shen YH; Cai JB; Dong RZ; Shi YH; Sun HC; Shi YG; Zhou J; Fan J; Ke AW; Yang LX; Shi GM
Theranostics; 2019; 9(16):4678-4687. PubMed ID: 31367249
[No Abstract] [Full Text] [Related]
12. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Job S; Rapoud D; Dos Santos A; Gonzalez P; Desterke C; Pascal G; Elarouci N; Ayadi M; Adam R; Azoulay D; Castaing D; Vibert E; Cherqui D; Samuel D; Sa Cuhna A; Marchio A; Pineau P; Guettier C; de Reyniès A; Faivre J
Hepatology; 2020 Sep; 72(3):965-981. PubMed ID: 31875970
[TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma in the Era of Immunotherapy.
Manthopoulou E; Ramai D; Dhar J; Samanta J; Ioannou A; Lusina E; Sacco R; Facciorusso A
Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376451
[TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
Mou H; Yu L; Liao Q; Hou X; Wu Y; Cui Q; Yan N; Ma R; Wang L; Yao M; Wang K
BMC Cancer; 2018 Nov; 18(1):1105. PubMed ID: 30419854
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):343-350. PubMed ID: 33645367
[No Abstract] [Full Text] [Related]
18. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
Blair AB; Murphy A
Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
[TBL] [Abstract][Full Text] [Related]
19. Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles.
Beal EW; Cloyd JM; Pawlik TM
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33396821
[TBL] [Abstract][Full Text] [Related]
20. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.
Lee H; Ross JS
Therap Adv Gastroenterol; 2017 Jun; 10(6):507-520. PubMed ID: 28567120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
